On July 29, Procter & Gamble fell 3.01% in pre-market trading, trading at $145.0/share, with turnover of $11.164 million. The decline was triggered by the company's fiscal Q4 earnings report revealing a revenue miss and year-over-year earnings contraction.

Procter & Gamble reported Q4 adjusted EPS of $1.43, slightly beating the consensus estimate of $1.41, but net sales of $21.203 billion fell short of the $21.379 billion estimate. More critically, organic revenue growth came in flat at 0%, significantly missing the 1.85% analyst expectation. Earnings per share declined 3.38% year-over-year from $1.48 in the prior-year quarter, signaling profitability compression. UBS had previously warned that Q4 organic sales growth would decelerate to 1.4%, below the Street's 1.7% consensus, and the actual result proved even weaker than that cautious forecast.

The stock had surged over 3% in the prior session after Barclays raised its price target to $152 and JPMorgan maintained an overweight rating with a $162 target. The sharp reversal reflects profit-taking as actual results confirmed revenue softness and margin deterioration that offset the modest EPS beat.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)